This site is intended for health professionals only
Wednesday 12 December 2018
Share |

Topic: Industry News

August 30, 2018
Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
 
"Today’s (27 August) approval by the European Commission of Kymriah® (tisagenlecleucel), the only CAR-T therapy licensed in two different types of blood cancers, moves us one step closer to providing this revolutionary therapy to appropriate patients in the UK. 
 
 
 

August 14, 2018
Only one third of pharmaceutical companies are compliant with Europan anti-counterfeiting measures, according to a representative group.

Only one third of pharmaceutical companies are compliant with Europan anti-counterfeiting measures, according to a representative group.
 
In a letter sent last week (6 August), the European Medicines Verification Organisation (EMVO) said that of the 2,291 pharmaceutical companies that have to connect to the European Medicines Verification System (EMVS) in less than six months, only 841 (36%) have signed the required agreement. 
 

July 18, 2018
Up to 42% of UK medicines may not be able to market their products in the European Union (EU) post-Brexit, a survey from the European Medicines Agency (EMA) has revealed.

Up to 42% of UK medicines may not be able to market their products in the European Union (EU) post-Brexit, a survey from the European Medicines Agency (EMA) has revealed.
 
The EMA said marketing authorisation holders for 58% of 693 centrally authorised products (CAPs) are on track to ensure they can continue to market their products once the UK leaves the EU in March 2019.
 

July 4, 2018
A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.

A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.
 
This month [June 2 2018], the organisation announced the launch of a Phase I Clinical Trial of its lead product, Hair Stimulating Complex, to treat the condition.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

June 20, 2018
Idorsia launches PRECISION – Phase 3 study with aprocitentan for resistant hypertension management in adults

Swiss biopharmaceuticals business Idorsia has announced that the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for managing resistant hypertension in adults [June 20 2018].
 

June 19, 2018
If passed, the legislation will provide hospital pharmacists with a legal defence for inadvertent dispensing errors

The UK’s Government is consulting on proposals to decriminalise dispensing errors for hospital pharmacists and technicians, it has announced.
 
The Department of Health and Social Care (DHSC) today (19 June) published a consultation on whether it should provide a legal defence for inadvertent dispensing errors for hospital pharmacists following the passing of a similar law protecting community pharmacists in April.
 

June 4, 2018
Tegsedi has been approved by the EMA for treatment of stage 1 and 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of its orphan drug Tegsedi™ (inotersen), for the treatment of Stage 1 or Stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR amyloidosis).1

 

 

April 6, 2018
Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells

Boehringer Ingelheim and OSE Immunotherapeutics have announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells.

 

March 20, 2018
Initiatives will use data analysis to identify ways to improve care and access to services for patients across multiple types of cancer

Novartis has announced the launch of two new Joint Working Projects with national Cancer Vanguard sites, which aim to identify ways to improve cancer patient care pathways and access to services.

 

December 15, 2017
The collaboration is centred on mRNA translation, which is a promising area of research with the potential to produce treatments that can target a fundamental characteristic of cancer cells

Cancer Research UK has announced the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology (CRT), and Celgene Corporation, to discover, develop and commercialise new anti-cancer treatments.


This arrangement represents an expansion of Cancer Research Technology’s theme-based translational model that now encompasses six industry partnerships, including this new collaboration with Celgene.  

November 9, 2017
The survey highlighted that medicines used by patients across Europe have integrated supply chains

EFPIA has published results of a survey underlining the sheer scale and importance of the medicines issues that must be addressed as part of the Brexit discussions in order to protect public health.

 

Commenting on the survey, EFPIA Director General, Nathalie Moll said. “The survey underlines the  scale of the task ahead. For life saving and life improving medicines, the EU and UK cannot afford to wait any longer to ensure that the necessary cooperation on medicines is in place from the day the UK leaves the EU.”

November 23, 2016
Recognised for her vision and leadership in the development of pharmacy services that ensure the safety and effectiveness of drug therapy, Professor Irene Krämer achieved public acclaim in Germany in 2016

Recognised for her vision and leadership in the development of pharmacy services that ensure the safety and effectiveness of drug therapy, Professor Irene Krämer achieved public acclaim in Germany in 2016

 

 

May 18, 2016
Efficacy and tolerability were maintained in patients who switched from reference infliximab to biosimilar infliximab over the duration of the study with the results showing comparability to those patients who continued treatment on biosimilar infliximab

Long term data from the pivotal phase III PLANETRA study over 102 weeks demonstrating the clinical efficacy and safety profile of biosimilar infliximab in RA patients, has been published in Annals of the Rheumatic Diseases this month.1

May 17, 2016
A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.
 

April 15, 2016
Available in new presentation strength of 0.1mg/ml to maximise accuracy and flexibility of dosing

Martindale Pharma, the UK-based leading international specialty pharmaceutical company, announced the UK launch of Phenylephrine, a new strength of the selective vasopressor drug for the treatment of hypotension associated with anaesthesia. Phenylephrine will be available in a 10ml ampoule at a strength of 0.1mg/ml.
 

April 1, 2016
Helapet have launched an improved 20mm Vented Vial Adapter, introducing a larger integrated air filter for rapid and reliable venting performance when drawing-up cytotoxic drugs and other hazardous medical solutions

Vial venting is a critical part of the transfer process between vial to syringe, especially when handling substances that could otherwise contaminate the user via spray droplets or harmful aerosols. The enhanced inline vent filter allows quick and efficient equalisation of sterile air in the vial for improved flow rates and effortless withdrawal.

 

March 8, 2016
Universities of Dundee (Scotland), & Cape Town (South Africa) partnering with Bayer (Germany)

World-leading medicinal chemistry and biology at the Universities of Dundee (Scotland) and Cape Town (South Africa) have been allied to the industrial expertise of the Pharmaceuticals Division of Bayer (Germany), one of the world’s leading pharma companies, in an effort to develop critically needed new treatments for tuberculosis (TB).
 

January 26, 2016
Ecolab Contamination Control, a worldwide provider of leading products and services for the control of microbial contamination in the cleanroom environment, has launched a unique product that will revolutionise the process of transfer disinfection within the pharmaceutical industry

Ecolab Contamination Control, a worldwide provider of leading products and services for the control of microbial contamination in the cleanroom environment, has launched a unique product that will revolutionise the process of transfer disinfection within the pharmaceutical industry.
 

 

January 18, 2016
C-level leaders from GSK, Novartis and Lilly have recently aligned in an effort to set out a new minimum standard or performance from their respective companies

C-level leaders from GSK, Novartis and Lilly have recently aligned in an effort to set out a new minimum standard or performance from their respective companies. They will announce their intentions at the eyeforpharma Barcelona Summit where a ‘new business plan’ for the industry comprising collaboration, culture and customer-centricity will be proposed.

 

Speaking ahead of the conference, David Epstein, CEO Pharmaceuticals, Novartis stressed a personal commitment:

 

January 18, 2016
Medi-Dose/EPS is pleased to announce it has expanded its line of compounding products to include ISO-MED’s Cleanroom Wipers and Supplies

Medi-Dose/EPS is pleased to announce it has expanded its line of compounding products to include ISO-MED’s cleanroom wipers and supplies. These additions complement EPS’s growing line of compounding products.

 

All ISO-MED Cleanroom Wipers are USP <797> compliant and are available in both sterile and non-sterile formats. Rated highly for their non-shedding characteristics, the wipers are available in both 9” x 9” and 12” x 12” sizes.

 

October 30, 2015
The Centre for Process Innovation (CPI) is part of a UK based consortium developing technologies that will spearhead the commercialisation of intelligent pharmaceutical packaging

The project titled ‘REMEDIES’, launched in 2014 and due for completion March 2018, is headed by GlaxoSmithKline with research led by the University of Cambridge’s Institute for Manufacturing. It brings together key players in the pharmaceutical supply chain to bring new emerging technologies to market that have the potential to improve medicine manufacturing and supply and offer more personalised, faster and cheaper drug delivery.

 

August 10, 2015
The solution by Schreiner MediPharm and Edelmann: the package insert is easy to access by pharmacists and patients without affecting the first-opening protection of the pack

Schreiner MediPharm has developed in a joint project with the packaging manufacturer Edelmann an innovative solution that makes important product information accessible without opening the pharmaceutical pack. The packaging solution is based on the requirements of the EU Falsified Medicines Directive 2011/62/EU.

 

July 22, 2015
Secukinumab is an innovative new treatment licensed for use in adults with moderate-to-severe plaque psoriasis

The National Institute for Health and Care Excellence (NICE) has issued technology appraisal guidance for Cosentyx™ (secukinumab). Secukinumab is an innovative new treatment licensed for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic* therapy. (1)

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine